Has Mikayel Grigoryan, MD received payments from drug or device companies?

Yes. Drug and device makers reported $180,011 in general payments to Mikayel Grigoryan, MD across 640 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Mikayel Grigoryan, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Mikayel Grigoryan, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Mikayel Grigoryan, MD

Neurological Surgery · Glendale, CANPI 1801003686

Payments from drug & device makers

$180,011in general payments, 2019–2025

Across 640 payments — averaging $281.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Genentech, Inc.$75K
Genentech USA, Inc.$27K
Microvention, Inc.$27K
Penumbra, Inc.$14K
AstraZeneca$12K
Stryker$9K
plus $15K from 51 others

What the payments were for

Consulting fees$24,04523%
Speaking & faculty fees$38,87937%
Travel & lodging$13,07112%
Food & beverage$29,02428%
Education$770%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Genentech, Inc.	20	$75,041
Genentech USA, Inc.	27	$27,393
Microvention, Inc.	46	$26,623
Penumbra, Inc.	46	$14,176
AstraZeneca(2 entities)	45	$12,074
Stryker	141	$9,392
Imperative Care, Inc	44	$3,563
Johnson & Johnson(2 entities)	58	$3,010
Abbott	42	$2,061
Medtronic(3 entities)	25	$1,633
Amgen(2 entities)	15	$501
Viz.ai, Inc.	2	$460
SK Life Science, Inc.	15	$452
Portola Pharmaceuticals, LLC	9	$292
AbbVie	13	$271
Balt USA, LLC	2	$261
Scientia Vascular	1	$240
Boston Scientific	4	$237
Chiesi USA, Inc.	5	$227
Novartis	11	$197
Microtransponder, Inc.	1	$177
ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)	9	$170
Teva Pharmaceuticals USA, Inc.	6	$161
Novo Nordisk	2	$140
Janssen Scientific Affairs, LLC	1	$106
Pfizer	4	$91
Terumo Medical Corporation	2	$83
Biogen	4	$81
UCB, Inc.	3	$70
GE HealthCare	3	$67
CSL Behring	3	$62
Kyowa Kirin, Inc.	3	$60
Eisai Inc.	3	$54
MDD US Operations, LLC	2	$41
EMD Serono, Inc.	1	$34
Neurelis, Inc.	1	$34
Lilly USA, LLC	1	$32
Sanofi	1	$30
Bristol Myers Squibb	1	$28
Route 92 Medical, Inc.	1	$27
Amneal Pharmaceuticals LLC	1	$27
Teleflex LLC	1	$26
Livanova USA, Inc.	1	$24
Acorda Therapeutics, Inc	1	$24
Takeda Pharmaceuticals U.S.A., Inc.	1	$24
Merz Pharmaceuticals, LLC	1	$23
Avanir Pharmaceuticals, Inc.	1	$23
Adamas Pharmaceuticals, Inc.	1	$22
Neural Analytics, Inc.	1	$21
Akcea Therapeutics, Inc.	1	$20
E.r. Squibb & Sons, L.L.C.	1	$20
Biohaven Pharmaceuticals, Inc.	1	$19
TG Therapeutics, Inc.	1	$19
Kestra Medical Technology Services, Inc.	1	$18
Argenx US, Inc.	1	$18
Biohaven Pharmaceutical Holding Company Ltd.	1	$14
B. Braun Interventional Systems Inc.	1	$14

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$180,011 in reported general payments places this provider in the 85th percentile of 773 neurological surgery providers in California.

See all neurological surgery providers in California →

Medicare billing

Part B allowed, 2024

$132,928

Medicare patients

278

Services billed

706

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
ClopidogrelClopidogrel Bisulfate	88	$257
Levetiracetam	18	$216

Paid to pharmacies, not to this prescriber.

Other neurological surgery in Glendale

Geoffrey ManleySan Francisco$24.9M
Christopher AmesSan Francisco$7.1M
Jamshid SalehRedding$4.1M
Bruce McCormackSan Francisco$3.9M
Andrew SchreiberSanta Ana$3.9M
Larry KhooLos Angeles$3M
Jennie TaylorSan Francisco$2.7M
Joseph CiacciSan Diego$2.6M
Nicholas ButowskiSan Francisco$2.4M
Samy AbdouSan Diego$2.4M

See the full list for California →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →